nach oben

Current Geriatrics Reports

Erschienen in:

09.08.2017 | Surgical Care for the Geriatric Patient (F Luchette and R Gonzalez, Section Editors)

Breast Cancer Care in the Elderly Patient

verfasst von: Grace Martin, Elizabeth Shaughnessy

Erschienen in: Current Geriatrics Reports | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

As women continue to live longer, physicians adapt to treating well-described diseases such as breast cancer. Here we provide a comprehensive evidence-based review of the treatment of breast cancer in the elderly patient.

Recent Findings

Previous studies conducted to determine optimal treatment for breast cancer have primarily included younger, healthier women. Despite favorable tumor biology, older women are less likely to receive standard of care treatments relative to breast reconstruction, postoperative radiation, and adjuvant chemotherapy. Frailty is cited as a reason for not offering or receiving therapies. There are no strict definitions of frailty for this specific population, but there are general guidelines for older cancer patients, with a lower specificity than desired.

Summary

Treatment recommendations for older women vary little from those for younger women. However, the paucity of data for the older age group within trials raises the question of the basis of evidence. Risks of treatment need to be evaluated relative to life expectancy.

The World Bank, World Development Indicators. Life expectancy at birth, total (years) | Data. 2017. In : Data.worldbank.org. http://data.worldbank.org/indicator/SP.DYN.LE00.IN. Accessed 9 Feb 2017.

Yancik R, Wesley MN, Ries LA, Havlik RJ, Edwards BK, Yates JW. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA. 2001;285:885–92. doi:10.1001/jama.285.7.885.CrossRefPubMed

Hamnett KE, Subramanian A. Breast reconstruction in older patients: a literature review of the decision-making process. J Plast Reconstr Aesthet Surg. 2016;69:1325–34. doi:10.1016/j.bjps.2016.06.003.CrossRefPubMed

American Cancer Society. Cancer facts & figures 2017. 2017. In: Cancer.org. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2017.html. Access 9 Feb 2017.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2017;67:7–30. doi:10.3322/caac.21387.CrossRefPubMed

•• Pettke E, Ilonzo N, Ayewah M, Tsantes S, Estabrook A, Ma AMT. Short-term, postoperative breast cancer outcomes in patients with advanced age. Am J Surg. 2016;212:677–81. doi:10.1016/j.amjsurg.2016.06.007. Thorough overview of the likely postoperative complication risks in the elderly with breast cancer, using the National Surgical Quality Improvement Program database CrossRefPubMed

Balducci L. Management of cancer in the elderly. Oncology, 1 Feb 2006, p 135. Expanded Academic ASAP, go.galegroup.com/ps/i.do?p=EAIM&sw=w&u=ucinc_main&v=2.1&id=GALE%7CA142723166&it=r&asid=43bf8457e578a9a35d77fc26933e3eb4.ist 2000;5:224–237. Accessed 9 Feb 2017.

Struck AE, Siu AL, Weiland GD, Adams J, Rubenstein LZ. Comprehensive geriatric assessment: a meta-analysis of controlled trials. Lancet. 1993;342:1032–6. doi:10.1016/0140-6736(93)92884-V.CrossRef

Bellera CA, Raingray M, Mathoulin-Pelissier S, Mertens C, Delva F, Fonck M, et al. Screening older cancer patients: first evalution of the G-8 geriatric screening tool. Ann Oncol. 2012;23:2166–72. doi:10.1093/annonc/mdr587.CrossRefPubMed

10.

•• Petit-Monegar A, Rainfray M, Soubeyran P, Bellera CA, Mathoulin-Pelissier S. Detection of frailty in elderly cancer patients: improvement of the G8 screening test. J Geriatric Oncol. 2016;7:99–107. doi:10.1016/j.jgo.2016.01.004. A practical, short assessment of frailty among patients 70 years of age and older CrossRef

11.

Weiss A, Noorbakhsh A, Tokin C, Chang D, Blair SL. Hormone receptor-negative breast cancer: undertreatment of patients over 80. Ann Surg Oncol. 2013;20:3274–3278. Erratum in: Ann Surg Oncol 2014:21:S785. doi:10.1245/s10434-013-3115-2.CrossRefPubMed

12.

Biganzoli L, Wildiers H, Oakman C, Marotti L, Loibl S, Kunkler I, et al. Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). Lancet Oncol. 2012;12:e148–60. doi:10.1016/S1470-2045(11)70383-7.CrossRef

13.

Angarita FA, Chesney T, Elser C, Mulligan AM, McCready DR, Escallon J. Treatment patterns of elderly breast cancer patients at two Canadian cancer centres. Eur J Surg Oncol. 2015;41:625–34. doi:10.1016/j.ejso.2015.01.02.028.CrossRefPubMed

14.

Cyr A, Gillanders WE, Aft RL, Eberlein TJ, Margenthaler JA. Breast cancer in elderly women (≥80 years): variation in standard of care? J Surg Oncol. 2011;103:201–6. doi:10.1002/jso.21799.CrossRefPubMed

15.

Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LA, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106 doi:10.1093/jnci/dju055.

16.

Hadj P, Jackisch C, Bolten W, Blettner M, Hindenburg HJ, Klein P, et al. Compliance and arthralgia in clinical therapy: the COMPACT trial, assessing the incidence of arthralgia, and compliance within the first year of adjuvant anastrozole therapy. Ann Oncol. 2014;25:372–7. doi:10.1093/annonc/mdt513.CrossRef

17.

Freedman RA, Vaz-Luis I, Barry WT, Li H, Lin NU, Winer EP, et al. Patterns of chemotherapy, toxicity, and short-term outcomes for older women receiving adjuvant trastuzumab-based therapy. Breast Cancer Res Treat. 2014;145:491–501. doi:10.1007/s10549-014-2968-9.CrossRefPubMed

18.

Van de Water W, Bastiaannet E, Dekkers OM, de Craen AJ, Westendoop RG, Voogd AC, et al. Adherence to treatment guidelines and survival in patients with early-stage breast cancer by age at diagnosis. Br J Surg. 2012;99:813–20. doi:10.1002/bjs.8743.CrossRefPubMed

19.

Wallweiner CW, Hartkopf AD, Grabe E, Wallweiner M, Taran FA, Fehm T, et al. Adjuvant chemotherapy in elderly patients with primary breast cancer: are women ≥65 undertreated? J Cancer Res Clin Oncol. 2016;142:1847–53. doi:10.1007/200432-016-2194-4.

20.

Malik MK, Tartter PI, Belfer R. Undertreated breast cancer in the elderly. J Cancer Epidemiol. 2013;2013:893104. doi:10.1155/2013/893104.CrossRefPubMedPubMedCentral

21.

Bouchardy C, Rapiti E, Blagojevic S, Vlastos AT, Vlastos G. Older female cancer patients: importance, causes, and consequences of undertreatment. J Clin Oncol. 2007;25:1858–69. doi:10.1200/JCO.2006.10.4208.CrossRefPubMed

22.

Diab SG, Elledge RM, Clark GM. Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst. 2000;92:550–6. doi:10.1093/jnci/192.7.550.CrossRefPubMed

23.

Pierga JY, Girre V, Laurence V, Asselain B, Die’ras V, Jouve M, et al. Characteristics and outcome of 1755 operable breast cancers in women over 70 years of age. Breast. 2004;13:369–75. doi:10.1016/j.breast.2004.04.012.CrossRefPubMed

24.

NCCN clinical practice guidelines in oncology (NCCN Guidelines), Breast Cancer. Version 1.2016. J Natl Compr Cancer Network 2016:14:324–354.

25.

Kemeny MM. Surgery in older patients. Semin Oncol. 2004;31:175–84. doi:10.1053/j.seminoncol.2003.12.028.CrossRefPubMed

26.

Fisher B, Anderson S, Bryant J, Margolese R, Deutsch M, Fisher ER, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy and lumpectomy plus radiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347:1233–41. doi:10.1056/NEJMoa022152.CrossRefPubMed

27.

Lichter AS, Lippman ME, Danforth DN Jr, d’Angelo T, Steinberg SM, deMoss E, et al. Mastectomy versus breast-conserving therapy in the treatment of stage I and II carcinoma of the breast: a randomized trial at the National Cancer Institute. J Clin Oncol. 1992;10:976–83. doi:10.1200/jco.1992.10.6.976.CrossRefPubMed

28.

Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347:1227–32. doi:10.1056/NEJMoa020989.CrossRefPubMed

29.

Agarwal S, Pappas L, Neumayer L, Kokeny K, Agarwal J. Effect of breast conservation therapy vs. mastectomy on disease-specific survival for early-stage breast cancer. JAMA Surg. 2014;149:267–74. doi:10.1001/jamasurg.2013.3049.CrossRefPubMed

30.

Hwang ES, Lichtensztajn DY, Gomez SL, Fowble B, Clarke CA. Survival after lumpectomy and mastectomy for early stage invasive breast cancer: the effect of age and hormone receptor status. Cancer. 2013;119:1402–11. doi:10.1002/cncr.27795.CrossRefPubMed

31.

Hofvind S, Holen AT, Roman M, Sebuodegard S, Akslen LA. Women treated with breast conserving surgery do better than those with mastectomy independent of detection mode, prognostic and predictive tumor characteristics. Eur J Surg Oncol. 2015;41:1417–22. doi:10.1016/j.ejso.2015.07.002.CrossRefPubMed

32.

Hutchins LF, Unger JM, Crowley JJ, Coltman CA, Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999;341:2061–7. doi:10.1056/NEJM199120303412706.CrossRefPubMed

33.

• Mamtani A, Gonzalez JJ, Neo D, Slanetz P, Houlihan MJ, Herold C, et al. Early-stage breast cancer in the octagenarian: tumor characteristics, treatment choices, and clinical outcomes. Ann Surg Oncol. 2016;23:3371–8. doi:10.1245/s10434-016-5368-z. Good overview of the tumor types relative to outcomes in the elderly breast cancer patient CrossRefPubMedPubMedCentral

34.

Giuliano AE, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases. Ann Surg. 2010;252:426–33. doi:10.1097/SLA.0b013e3181f08f32.CrossRefPubMed

35.

Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11:927–33. doi:10.1016/s1470-2045(10)70207-2.CrossRefPubMedPubMedCentral

36.

Ashikaga T, Krag DN, Land SR, Julian TB, Anderson SJ, Brown AM, et al. Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection vs. axillary dissection. J Surg Oncol. 2010;102:111–8. doi:10.1002/jso.21535.CrossRefPubMedPubMedCentral

37.

Martelli G, Borachi P, Ardoino I, Lozza L, Behm S, Vetrella G, et al. Axillary dissection vs. no axillary dissection in older patients with T1N0 breast cancer: 15-year results of a randomized controlled trial. Ann Surg. 2012;256:920–4. doi:10.1097/SLA.0b013e31827660a8.CrossRefPubMed

38.

International Breast Cancer Study Group, Rudenstam C-M, Zahrieh D, Forbes JF, Crivellari D, Holmberg SB, et al. Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93. J Clin Oncol. 2006;24:337–44. doi:10.1200/JCO.2005.01.5784.CrossRef

39.

Fenlon D, Frankland J, Foster CL, Brooks C, Coleman P, Payne S, et al. Living into old age with the consequences of breast cancer. Eur J Oncol Nurs. 2013;17:311–6. doi:10.1016/j.ejon.2012.08.004.CrossRefPubMed

40.

Song D, Slater K, Papsdorf M, VanLaeken N, Zhong T, Hazen A, et al. Autologous breast reconstruction in women older than 65 years versus women younger than 65 years: a multi-center analysis. Ann Plast Surg. 2016;76:155–63. doi:10.1097/sap.0000000000000527.CrossRefPubMed

41.

Andreae MH, Andreae DA. Regional anaesthesia to prevent chronic pain after surgery: a Cochrane systematic review and meta-analysis. Br J Anaesth. 2013;111:711–20. doi:10.1093/bja/aet213.CrossRefPubMedPubMedCentral

42.

Schnabel A, Reichl SU, Kranke P, Pogatzki-Zahn EM, Zahn PK. Efficacy and safety of paravertebral blocks in breast surgery: a meta-analysis of randomized controlled trials. Brit J of Anaesth. 2010;105:842–852. Erratum in: Br J Anaesth 2013:111:522. doi:10.1093/bja/aeq265.CrossRef

43.

Sato M, Shirakami G, Fukuda K. Comparison of general anesthesia and monitored anesthesia care in patients undergoing breast cancer surgery using a combination of ultrasound-guided thoracic paravertebral block and local infiltration anesthesia: a retrospective study. J Anesth. 2015;30:244–51. doi:10.1007/s00540-015-2111-z.CrossRefPubMed

44.

Hughes KS, Schnaper LA, Berry D, Cirrincione C, McCormick B, Shank B, et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med. 2004;351:971–7. doi:10.1056/NEJMoa040587.CrossRefPubMed

45.

• Hughes KS, Schnaper LA, Bellon JR, Cirrincione CT, Berry DA, McCormick B, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol. 2013;31:2382–7. doi:10.1200/JCO.2012.45.2615. Use of radiotherapy in women over the age of 70 with breast cancer resected with lumpectomy and whether radiation improves survival CrossRefPubMedPubMedCentral

46.

Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans V, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomized trials. Lancet. 2005;366:2087–106. doi:10.1016/S0140-6736(05)67887-7.CrossRefPubMed

47.

LeMasters T, Madhavan S, Sambamoorthi U. Comparison of the initial local-regional treatment received for early-stage breast cancer, between elderly women in Appalachia and a United States-based population: good and bad news. Glob J Breast Cancer Res. 2016;4:10–9. doi:10.20941/2309-4419.2016.04.2.CrossRef

48.

Shaitelman SF, Lin HY, Smith BD, Shen Y, Bedrosian I, Marsh GD, et al. Practical implications of the publication of consensus guidelines by the American Society for Radiation Oncology: accelerated partial breast irradiation and the National Cancer Data Base. Int J Radiat Oncol Biol Phys. 2016;94:338–48. doi:10.1016/j.ijrobp.2015.10.059.CrossRefPubMed

49.

Smith BD, Gross CP, Smith GL, Galusha DH, Bekelman JE, Haffty BG. Effectiveness of radiation therapy for older women with early breast cancer. J Natl Cancer Inst. 2006;98:681–90. doi:10.1093/jnci/djj/86.CrossRefPubMed

50.

Shen X, Anne PR, Keith SW, Wojcieszynski A, Mishra MV, Bar-Ad V, et al. Radiation therapy use and outcomes among older women with ER-positive and ER-negative stage I breast cancer. Am J Clin Oncol. 2014;37:241–7. doi:10.1097/coc.0b013e318271b326.CrossRefPubMed

51.

van de Water W, Bastiaannet E, Scholten AN, Kiderlen M, de Craen AJ, Westendorp RG, et al. Breast-conserving surgery with or without radiotherapy in older breast patients with early stage breast cancer: a systematic review and meta-analysis. Ann Surg Oncol. 2014;21:786–94. doi:10.1245/s10434-013-3374-y.CrossRefPubMed

52.

Mogel HD, Clark C, Dodson R, Fino N, Howard-McNatt M. Outcomes after mastectomy and lumpectomy in elderly patients with early-stage breast cancer. Ann Surg Oncol. 2016:1–8. doi:10.1245/e10434-016-5582-8.

53.

Nagar H, Yan W, Christos P, Chao KS, Nori D, Ravi A. Older patients with early-stage breast cancer: adjuvant radiation therapy and predictive factors for cancer-related death. Am J Clin Oncol. 2014; doi:10.1097/coc.0000000000000144.CrossRefPubMed

54.

Daugherty E, Daugherty M, Bogart J, Shapiro A. Adjuvant radiation improves survival in older women following breast-conserving surgery for estrogen receptor negative breast cancer. Clin Breast Cancer. 2016;16:500–6. doi:10.1016/j.clbc.2016.06.17.CrossRefPubMed

55.

Griggs JJ, Culakova E, Sorbero ME, Poniewierski MS, Wolff DA, Crawford J, et al. Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens. J Clin Oncol. 2007;25:2522–7. doi:10.1200/JCO.2006.10.2749.CrossRefPubMed

56.

Elkin EB, Hurria A, Mitra N, Schrag D, Panageas KS. Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort. J Clin Oncol. 2006;24:2757–64. doi:10.1200/JCO.2005.03.6053.CrossRefPubMed

57.

Giordano SH, Duan Z, Kuo YF, Hortobagyi GN, Goodwin JS. Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol. 2006;24:2750–6. doi:10.1200/JCO.2005.02.3028.CrossRefPubMed

58.

Hassett MJ, Silver SM, Hughes ME, Blayney DW, Edge SB, Herman JG, et al. Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. J Clin Oncol. 2012;30:2218–26. doi:10.1200/JCO.2011.38.5740.CrossRefPubMedPubMedCentral

59.

Senkus E, Kyriakides S, Penault-Llorca F, Ohno S, Penault-Llorca F, Poortmans P, et al. Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26:v8–30. doi:10.1093/annonc/mdu298.CrossRefPubMed

60.

Muss HB, Berry DA, Cirrincione CT, Theodoulou M, Mauer AM, Kornblith AB, et al. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med. 2009;360:2055–2065. Erratum in N Engl J Med 2009:361:1714. doi:10.1056/NEJMoa0810266.CrossRefPubMedPubMedCentral

61.

von Minckwitz G, Conrad B, Reimer T, Decker T, Eidtmann H, Eiermann W, et al. A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52). Cancer. 2015;121:3639–48. doi:10.1002/cncr.29506.CrossRef

62.

von Minckwitz G, Reimer T, Potenberg J, Conrad B, Schurer U, Eidtmann H, et al. The phase III ICE study: adjuvant ibandronate with or without capecitabine in elderly patients with moderate or high risk early breast cancer. Cancer Res. 2015;75:S3–04. doi:10.1158/1538-7445.SABCS14.S3-04.CrossRef

63.

Sun J, Chia S. Adjuvant chemotherapy and HER-2-directed therapy for early-stage breast cancer in the elderly. Br J Cancer. 2017;116:4–9. doi:10.1038/bjc.2016.360.CrossRefPubMed

64.

Jones S, Holmes FA, O’Shaughnessy J, Blum JL, Vukelja SJ, McIntyre KJ, et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7 year followup of US Oncology Research Trial 9735. J Clin Oncol. 2009;27:1177–83. doi:10.1200/JCO.2008.18.4028.CrossRefPubMed

65.

Owusu C, Lash TL, Silliman RA. Effectiveness of adjuvant tamoxifen therapy among older women with early stage breast cancer. Breast J. 2007;13:374–82. doi:10.1111/j.1524-4741.2007.00445.x.CrossRefPubMed

66.

Fyles AW, McCready DR, Manchul LA, Trudeau ME, Merante P, Pintilie M, et al. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med. 2004;351:963–70. doi:10.1056/NEJMoa040595.CrossRefPubMed

67.

Hind D, Wyld L, Reed MW. Surgery, with or without tamoxifen, vs. tamoxifen alone for older women with operable breast cancer: Cochrane review. Br J Cancer. 2007;96:1025–9. doi:10.1038/sj.bjc.6603600.CrossRefPubMedPubMedCentral

68.

Colleoni M, Giobbie-Hurder A, Regan MM, Coates AS, Mastropasqua MG, Dell’Orto P, et al. Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. J Clin Oncol. 2011;29:1117–24. doi:10.1200/JCO.2008.17.0829.CrossRefPubMedPubMedCentral

69.

Arimidex T, Alone or in Combination (ATAC) Trialists’ Group, Forbes JF, Cuzick J, Buzdar A, Howell A, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008;9:45–53. doi:10.1016/S1470-2045(07)70385-6.CrossRef

70.

Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Livingston RB, et al. Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA 17 trial of extended adjuvant letrozole. Ann Oncol. 2013;24:355–61. doi:10.1093/annonc/mds330.CrossRefPubMed

71.

Slamon DJ, Eiermann W, Robert NJ, Giermek J, Martin M, Jasiowka M, et al. Ten year follow-up of the BCIRG-006 trial comparing doxorubicin plus cyclophosphamide followed by docetaxel with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in HER2 + early breast cancer patients. Cancer Res. 2016;76:S5–04. doi:10.1158/1538-7445.SABCS15-S5-04.CrossRef

72.

Brollo J, Curigliano G, Disalvatore D, Marrone BF, Criscitiello C, Bagnardi V, et al. Adjuvant trastuzumab in elderly with HER-2 positive breast cancer: a systematic review of randomized controlled trials. Cancer Treat Rev. 2013;39:44–50. doi:10.1016/jctrv.2012.03.009.CrossRefPubMed

73.

Chavez-MacGregor M, Zhang N, Buchholz TA, Zhang Y, Niu J, Elting L, et al. Trastuzumab-related cardiotoxicity among older patients with breast cancer. J Clin Oncol. 2013;31:4222–8. doi:10.1200/JCO.2013.48.7884.CrossRefPubMedPubMedCentral

74.

Russell SD, Blackwell KL, Lawrence J, Pippen JE Jr, Roe MT, Wood F, et al. Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant Breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. J Clin Oncol. 2010;28:3416–21. doi:10.1200/JCO.2009.23.6950.CrossRefPubMed

75.

Freedman RA, Hughes ME, Ottesen RA, Weeks JC, He Y, Wong YN, et al. Use of adjuvant trastuzumab in women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer by race/ethnicity and education within the National Comprehensive Cancer Network. Cancer. 2013;119:839–46. doi:10.1002/cncr.27831.CrossRefPubMed

76.

Vaz-Luis I, Keating NL, Lin NU, Lii H, Winer EP, Freedman RA. Duration and toxicity of adjuvant trastuzumab in older patients with early-stage breast cancer: a population-based study. J Clin Oncol. 2014;32:927–34. doi:10.1007/s10549-014-2668-9.CrossRefPubMedPubMedCentral

77.

Chen J, Long JB, Hurria A, Owusu C, Steingart RM, Gross CP. Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Col Cardiol. 2012;60:2504–12. doi:10.1016/j.jacc.2012.07.068.CrossRef

78.

• Miles D, Baselga J, Amadori D, Sunpaweravong P, Semiglazov V, Knott A, et al. Treatment of older patients with HER@-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controled phase III trial (CLEOPATRA). Breast Cancer Res Treat. 2013;142:89–99. doi:10.1007/s10549-013-2710-z. Analysis of the subset of elderly patients in the pivotal CLEOPATRA trial CrossRefPubMedPubMedCentral

79.

Loibl S, Jackisch C, Schneeweiss A, Schmatioch S, Aktas B, Denkert C, et al. Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial. Ann Oncol. 2016;

80.

Gianni L, Penkowski T, Im YH, Tseng LM, Liu MC, Lluch AS, et al. 5-year analysis of neodjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicenter, open-label, phase 2 randomised trial. Lancet Oncol. 2016;17:791–800. doi:10.1016/S1470-2045(16)00163-7.CrossRefPubMed

81.

Smyth LM, Iyengar NM, Chen MF, Popper SM, Patail S, Wasserheit-Lieblich C, et al. Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study. Breast Cancer Res Treat. 2016;158:91–7. doi:10.1007/s10549-016-3851-7.CrossRefPubMedPubMedCentral

82.

Perez EA, Lopez-Vega JM, Petit T, Zamagni C, Easton V, Kamber J, et al. Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results. Breast Cancer Res. 2016;18:126. doi:10.1186/s13058-016-0773-6.CrossRefPubMedPubMedCentral

83.

Hurria A, Togawa K, Mohile SG, Owusu C, Klepin HD, Gross CP, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011;29:3457–65. doi:10.1200/JCO.2011.34.7625.CrossRefPubMedPubMedCentral

84.

• Extermann M, Boler I, Reich RR, Lyman GH, Brown RH, DeFelice J, et al. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer. 2012;118:3377–86. doi:10.1002/cncr.26646. Helpful in choosing whether to initiate chemotherapy in the treatment of the elderly patient with breast cancer CrossRefPubMed

Titel: Breast Cancer Care in the Elderly Patient
verfasst von: Grace Martin
Elizabeth Shaughnessy
Publikationsdatum: 09.08.2017
Verlag: Springer US
Erschienen in: Current Geriatrics Reports / Ausgabe 3/2017
Elektronische ISSN: 2196-7865
DOI: https://doi.org/10.1007/s13670-017-0218-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Breast Cancer Care in the Elderly Patient

Abstract

Purpose of Review

Recent Findings

Summary

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2017

Prevention of Falls and Frailty in Older Adults with Diabetes

Prostate Cancer in the Elderly Male: Diagnostic and Management Considerations

Thoracic Surgery in Older Patients

Comparative Effectiveness for Glycemic Control in Older Adults with Diabetes

Reduction of Cognitive Decline in Patients with or at High Risk for Diabetes

Erratum to: Comparative Effectiveness for Glycemic Control in Older Adults with Diabetes

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin